Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 7.01M | 3.00M | 2.45M | 377.00K | 500.00K | 0.00 |
Gross Profit | -35.49M | -3.04M | -3.97M | -3.24M | -85.00K | -23.00K |
EBITDA | -4.63B | 29.67M | -75.74M | -99.41M | -55.90M | -35.81M |
Net Income | 72.88M | 39.79M | -64.17M | -88.98M | -50.35M | -34.33M |
Balance Sheet | ||||||
Total Assets | 43.89M | 30.66M | 33.12M | 53.98M | 86.98M | 19.78M |
Cash, Cash Equivalents and Short-Term Investments | 4.00B | 1.19M | 19.64M | 39.74M | 77.26M | 17.26M |
Total Debt | 9.31B | 31.86M | 48.73M | 36.64M | 0.00 | 14.96M |
Total Liabilities | 12.47M | 37.69M | 57.14M | 43.05M | 7.56M | 20.25M |
Stockholders Equity | 40.79M | -2.50M | -53.83M | -9.68M | 61.67M | 1.90M |
Cash Flow | ||||||
Free Cash Flow | -2.77B | -33.61M | -52.28M | -72.53M | -42.06M | -21.97M |
Operating Cash Flow | -2.77B | -33.55M | -52.04M | -70.98M | -40.59M | -21.91M |
Investing Cash Flow | -24.14M | -16.18M | 758.00K | -4.74M | -3.72M | -55.00K |
Financing Cash Flow | 2.49B | 31.28M | 31.17M | 38.21M | 104.31M | 33.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
49 Neutral | $10.85M | -0.74 | -202.86% | ― | 0.36% | -17.20% | |
49 Neutral | $10.83M | -0.20 | -228.99% | ― | -12.60% | 95.87% | |
45 Neutral | $17.09M | -0.32 | -69.30% | ― | -91.14% | 9.47% | |
45 Neutral | $9.45M | -0.44 | -4272.16% | ― | -66.40% | 65.99% | |
44 Neutral | $9.51M | 0.38 | -499.57% | ― | -73.36% | ― | |
40 Underperform | $7.92M | -1.28 | -121.14% | ― | -1.88% | 23.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On September 11, 2025, Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., completed a public offering of 28,750,000 shares of its common stock at $1.00 per share, raising approximately $26.9 million after expenses. The proceeds from this offering are intended for working capital and general corporate purposes, potentially impacting the company’s operational capabilities and market positioning.
The most recent analyst rating on (PAVM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
In its second quarter of 2025, PAVmed Inc. reported significant business developments and financial results. Lucid Diagnostics processed 2,756 EsoGuard tests, generating $1.2 million in revenue, and secured a Medicare LCD meeting for September 4, 2025. Veris Health completed financing and is advancing its implantable monitor towards FDA clearance, with strategic partnerships in place to enhance its commercial deployment. PAVmed’s financial results showed a GAAP net loss of $13.3 million, with a strengthened balance sheet and cash reserves of $4.0 million as of June 30, 2025.
The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
On July 29, 2025, PAVmed Inc. received a notification from Nasdaq granting an additional 180 days, until January 19, 2026, to comply with the minimum bid price requirement of $1 per share. The company had initially been given until July 22, 2025, to meet this requirement but failed to do so. Despite this, Nasdaq has allowed an extension, and PAVmed plans to explore all options to regain compliance. The company’s stock will continue to trade under the symbol ‘PAVM’ without interruption.
The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
On June 23, 2025, Veris Health Inc., a subsidiary of PAVmed Inc., completed a $2.5 million offering by selling shares and warrants to accredited investors, aimed at funding the development of its implantable physiological monitor and general operations. This strategic move enhances Veris’ financial position and provides investors with future participation rights, potentially strengthening its market presence and operational capabilities.
The most recent analyst rating on (PAVM) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
On June 18, 2025, PAVmed Inc. held its annual meeting of stockholders, where approximately 77.2% of shares were represented. During the meeting, stockholders elected management’s nominees for director, approved the issuance of common stock upon exercise of pre-funded warrants, amended the 2014 Long-Term Incentive Equity Plan to increase available shares, approved executive compensation, and ratified the appointment of Marcum LLP as the independent registered certified public accounting firm for 2025.
The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.